Top Ten most popular articles on Pharmafile.com this week
We’re now into 2017 in earnest and news of acquisitions, partnerships, R&D advancements and scandals are back in force. Cancer research has seen a number of breakthroughs in the past few weeks, and our most read piece last week has proven to be just as popular with readers this week.
Catch up with the most read stories on Pharmafile.com this week:
Research conducted by The Institute of Cancer Research (ICR), co-funded by Cancer Research UK, has discovered how cancer cells are able to spread through the human body, despite the physical restraints that usually stop this occurring.
MSD has filed Keytruda for Priority Review as combination treatment alongside chemotherapy; if approved, the company would have a head start on competitors also working on their own combination therapies.
Takeda has acquired US drug maker, Ariad Pharmaceuticals, in a deal worth $5.2 billion. Takeda has been looking to bolster its business with acquisitions for some time and has settled upon Ariad.
Pfizer has released the successful Phase 3 results to its biosimilar to AbbVie’s blockbuster Humira, meeting its primary endpoint in its REFLECTIONS B538-02 clinical study. The news builds upon the success that Pfizer has already achieved last year in building its biosimilar portfolio.
AstraZeneca has entered into a research collaboration, option and asset purchase agreement with APT Therapeutics. The deal focuses on APT’s lead candidate, APT102, a human recombinant apyrase therapy for those suffering from thrombotic diseases.
Amgen and Immatics will join forces to develop and commercialise novel T-cell engaging bispecific cancer immunotherapies.
Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in its global restructuring programme.
It has been announced that the Federal Trade Commission has approved Abbott Laboratories acquisition of St. Jude Medical for $25 billion, in a deal that was announced back in April 2016.
Shire is accused of bribing clinicians and physicians by using kickbacks to encourage the use of Dermagraft, a diabetic foot ulcer treatment.
What will be the key industry trends in 2017? Here at Pharmafile, we look ahead to what we expect could be some of the major trends that will reoccur through 2017.
As the year winds to a close, excitement is rising around the efficacy and availability …
The top ten news stories this week focus on herd immunity, as the Director of …